Correction to: Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study

Abstract

In the original publication, there were errors in some sentences that are corrected as below: In the keywords section, Page 1, Lines 1–2: the “Pertuzumab”, “Trastuzumab”, and “Hyaluronidase-zzxf” should all be replaced with “Pertuzumab, trastuzumab, and hyaluronidase-zzxf”. In the Introduction section, Page 2, Paragraph 3, Lines 10–11: “(Ctrough and area under the curve [AUC])” should be replaced with “[Ctrough and area under the curve (AUC)]”. In the Introduction section, Page 2, Paragraph 3, Lines 18–19: “2000 U/mL” currently spans over two lines; it should be on the same line. In the Materials and methods section, Study design, Lines 9–13: “(4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of doxorubicin plus cyclophosphamide (AC) every 3 weeks followed by 4 cycles of docetaxel every 3 weeks)” should be replaced with “[4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of doxorubicin plus cyclophosphamide (AC) every 3 weeks followed by 4 cycles of docetaxel every 3 weeks]”. In the Materials and methods section, Procedures, Paragraph 1, Lines 11–12: “HER2-targeted” currently spans over two lines; it should be on the same line. In the Materials and methods section, Procedures, Paragraph 1, Lines 12–13: “P IV” currently spans over two lines; it should be on the same line. In the Materials and methods section, Pertuzumab population pharmacokinetic analysis, Paragraph 2, Lines 13–19: “[hormone receptor status (estrogen receptoror progesterone receptor-positive, or estrogen receptorand progesterone receptor-negative), clinical stage (II–IIIA or IIIB–IIIC), and chemotherapy regimen (4 cycles of ddAC every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of AC every 3 weeks followed by 4 cycles of docetaxel every 3 weeks]” should be replaced with “[hormone receptor status (estrogen receptoror progesterone receptor-positive, or estrogen receptorand progesterone receptor-negative), clinical stage (II–IIIA or IIIB–IIIC), and chemotherapy regimen (4 cycles of ddAC every 2 weeks followed by paclitaxel once weekly for 12 weeks, or 4 cycles of AC every 3 weeks followed by 4 cycles of docetaxel every 3 weeks)]”. In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 18: “(F)” should be replaced with “(F)”, i.e., ‘F’ in italics. In the Results section, Pertuzumab population pharmacokinetic analysis, Page 4, Paragraph 1, Line 19: The original article can be found online at https:// doi. org/ 10. 1007/ s0028002104296-0.